Drug Approval | September 03, 2024
Lupin launches Doxorubicin Hydrochloride Liposome Injection in US
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
